Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Contact Us
Investors & News
Latest News
October 17, 2019
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
October 10, 2019
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
October 07, 2019
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports
Latest Presentations
October 17, 2019
Investor Presentation October 2019
Presentations
Events
October 10, 2019
Stealth Announces Co-Development Partnership with Alexion for Mitochondrial Disease
October 01, 2019
Cantor Global HC Conference
Financial Calendar
Media Relations
dna Communications
Lindsey Colegrove, 212-537-8771
media@stealthbt.com
Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com
